$80M Funding Will Help Expansion Develop RNA-targeted Therapies

$80M Funding Will Help Expansion Develop RNA-targeted Therapies

308194

$80M Funding Will Help Expansion Develop RNA-targeted Therapies

Expansion Therapeutics has raised $80 million in funding to support the development of its small molecule RNA platform, called SMiRNA, for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases. The Series B financing will help the drug development company use its platform to discover small molecules targeting RNA molecules — the intermediate molecules originating from DNA that carry the instructions for protein production — involved in disease processes. In addition to ALS, the company will…

You must be logged in to read/download the full post.